Walder Wyss with Vandria on its 2nd Series A closing
Hevolution Foundation and Dolby Family Ventures joined ND Capital as additional institutional investors bringing Series A funding in Vandria, advised by Walder Wyss, to a total of $30.7 million. Vandria’s lead CNS compound VNA-318 is a mitophagy inducer about to enter clinical development with a unique dual mode of action of immediate improvement of cognitive function paired with long-term disease-modifying effects.
Walder Wyss team
Walder Wyss advised Vandria on this round of financing with a team led by corporate/M&A partner Luc Defferrard (pictured) and which further included Ken Savioz (associate, corporate/M&A) and Anaïs Essinger (associate, corporate/M&A).
